Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (41-50 of 232) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanibKostandinos Sideras, Michael E Menefee, Jill K Burton, et al.
Leukemia & Lymphoma|July 16, 2005
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology GroupDouglas P Olson, Barbara J Taylor, Mei La, et al.
Cancer Letters|February 2, 2024
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patientsMorgan A Butrovich, Jiyue Qin, Xiaonan Xue, et al.
Breast Cancer Research and Treatment|November 16, 2011
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerElaina M Gartner, Paula Silverman, Michael Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Heart Failure Clinics|July 14, 2011
The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reportingAkm Hossain, Alice Chen, Percy Ivy, et al.
Journal of Biopharmaceutical Statistics|April 23, 2009
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experienceElisabeth I Heath, Patricia M LoRusso, S Percy Ivy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2026
Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigationHeekyung Lee, Allison Dunn, Sarah E Taylor, et al.
Cancer Chemotherapy and Pharmacology|May 5, 2010
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patientsJill Kolesar, Richard C Brundage, Marcia Pomplun, et al.
Pageof 24

Showing results (41-50 of 232) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanibKostandinos Sideras, Michael E Menefee, Jill K Burton, et al.
Leukemia & Lymphoma|July 16, 2005
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology GroupDouglas P Olson, Barbara J Taylor, Mei La, et al.
Cancer Letters|February 2, 2024
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patientsMorgan A Butrovich, Jiyue Qin, Xiaonan Xue, et al.
Breast Cancer Research and Treatment|November 16, 2011
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancerElaina M Gartner, Paula Silverman, Michael Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Heart Failure Clinics|July 14, 2011
The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reportingAkm Hossain, Alice Chen, Percy Ivy, et al.
Journal of Biopharmaceutical Statistics|April 23, 2009
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experienceElisabeth I Heath, Patricia M LoRusso, S Percy Ivy, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Cancer Chemotherapy and Pharmacology|May 20, 2026
Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigationHeekyung Lee, Allison Dunn, Sarah E Taylor, et al.
Cancer Chemotherapy and Pharmacology|May 5, 2010
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patientsJill Kolesar, Richard C Brundage, Marcia Pomplun, et al.
Pageof 24